INLYTA is a prescription medication that contains the active ingredient Axitinib. It is primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) in adults. This targeted therapy works by inhibiting certain proteins that promote the growth of cancer cells, helping to slow down or stop the progression of the disease.